Navigation Links
Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer
Date:3/11/2010

ABBOTT PARK, Ill., March 11 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental new drug application (sNDA) of a new six-month 45-mg formulation of Lupron® Depot (leuprolide acetate for depot suspension) for use in the palliative treatment of advanced prostate cancer.  Palliative treatment helps to relieve symptoms associated with advanced prostate cancer.  Lupron Depot works by suppressing the production of the hormone testosterone.  This decrease in testosterone, which helps slow or stop the growth of hormone-dependent cancer cells, may relieve pain and other symptoms related to advanced prostate cancer.  

"For many patients with advanced prostate cancer, Lupron Depot is an important treatment option because it can help manage the symptoms of their disease," said Eugene Sun, M.D., vice president, Global Pharmaceutical Development, Abbott. "Abbott is seeking approval for a new six-month formulation to provide greater convenience and dosing flexibility to physicians and patients who could benefit from this medication."

Lupron Depot is currently available in one-month (7.5 mg), three-month (22.5 mg) and four-month (30 mg) depot formulations.  Abbott's submission is supported by new data from a 48-week study involving 300 patients with prostate cancer.  Patients received a total of two injections, 24 weeks apart, and were followed for nearly one year to eva
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013  BioElectronics Corporation (OTC Pink: BIEL), ... comments on the FDA panel meeting for non-thermal shortwave ... – Pulsed Shortwave Therapy Meeting was held on May ... USA.  The focus of the meeting was very narrow, ... focus solely on the application of non-thermal shortwave diathermy ...
(Date:5/23/2013)... May 23, 2013 Halozyme Therapeutics, Inc. ... appointment of David A. Ramsay ... most recently Vice President, Corporate Development at Halozyme. ... "With his established financial management experience and ... working in our commercial group for the last ...
(Date:5/23/2013)... , May 23, 2013 Isis Pharmaceuticals, Inc. ... today announced that management will present a company overview at ... Conference on Thursday, May 30, 2013 at 8:40 a.m. ET ... live audio webcast of the presentation will be available on ... www.isispharm.com .  A replay will be available on the ...
Breaking Medicine Technology:BioElectronics and Pulsed Shortwave Therapy Make Progress 2Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference 2
... Pfizer Inc. (NYSE: PFE ) today announced, at the ... the chronic low back pain and painful diabetic peripheral neuropathy studies in ... continues in some areas of high unmet medical need, including cancer pain. ... (Logo:   http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO ...
... Heslin , MD of Bridge Street Medical Group will discuss use of health IT ... 20 , , , ... July 19 If a small general medical practice in ... health care for its patients, so can practices across the nation. That is the ...
Cached Medicine Technology:Pfizer Suspends Chronic Pain Studies in Tanezumab Clinical Trial Program; Some Studies Continue in Areas of Unmet Medical Need 2Hudson Valley Physician Testifies Before House Health Subcommittee Tuesday About Incentives for Adoption of Health Information Technology 2Hudson Valley Physician Testifies Before House Health Subcommittee Tuesday About Incentives for Adoption of Health Information Technology 3
(Date:5/23/2013)... it when a woman harried by hot flashes says ... study published online in Menopause , the journal ... with objective tests that what these women say about ... studies showed that hot flashes were related to memory ... though there was a relationship between hot flashes and ...
(Date:5/23/2013)... Susquehanna Health is now a ... training course for adolescents age 11 and up. ... Dr. Patricia Keener after a colleague’s toddler choked to ... who didn’t know how to provide first aid. Safe ... medical basis that aims to reduce the number of ...
(Date:5/23/2013)... An anti-cancer drug about to be tested in a ... a possible treatment for Alzheimer,s disease has failed to ... plague Alzheimer,s patients, according to results of a study ... a professor of neuroscience affiliated with the Evelyn F. ... of Florida, emphasized the importance of verifying promising research ...
(Date:5/23/2013)... The Rottenstein Law Group LLP, a New ... Tylenol Lawsuit Information Center at http://www.rotlaw.com/tylenol , dedicated ... who are considering filing lawsuits. , The painkiller ... liver damage, according to a 2009 report from the ... communication,” the FDA warned consumers against using more than ...
(Date:5/23/2013)... Former United States Vice President Dick Cheney served as ... Luncheon. , In front of 1,500 guests yesterday ... saying, "I am delighted to be here to have ... the Year Award. I think it's a tremendous recognition; ... a company like this because there are obviously a ...
Breaking Medicine News(10 mins):Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2Health News:Acadian Ambulance Honors Paramedic of the Year at Annual Luncheon 2
... this summer and a friend dares you to eat a raw ... hospital with a severe parasitic infection. Physicians at Washington University ... infection in six people who had consumed raw crayfish from streams ... years, but three have been diagnosed since last September; the latest ...
... ... statistics on the top-performing companies for the past six months, Jusuru International is the fastest ... ... has just released its statistics on the top-performing companies for the past six months, Jusuru ...
... Massachusetts Medical School report in the journal Nature Medicine ... malignant glioma, a pathway essential to the cancer,s ability ... that would stop the cancer,s ability to thrive. ... RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway ...
... infection improves patient outcomes, researchers say , TUESDAY, May ... ailment chronic obstructive pulmonary disease (COPD) do better when ... , COPD patients who were given antibiotics early in ... ventilation and less likely to have to be readmitted ...
... ... Version of Pearson Author Elana Zucker’s Best-selling Textbook, Being a Home Health Aide , ... Indianapolis, IN (PRWEB) May 25, 2010 ... decade, the Indiana Home and Hospice Care (IHHC) Foundation needed to quickly overhaul its outdated ...
... suggest that bacteria residing in the the human intestinal ... developing colon cancer. Scientists from the University of Florida ... of the American Society for Microbiology in San Diego, ... are more frequently detected in subjects with polyps, early ...
Cached Medicine News:Health News:Dangerous lung worms found in people who eat raw crayfish 2Health News:Dangerous lung worms found in people who eat raw crayfish 3Health News:Dangerous lung worms found in people who eat raw crayfish 4Health News:,Jusuru Tops New Company Launch Rankings, 2Health News:Novel RNA interference screening technique identifies possible path for malignant glioma treatment 2Health News:Quick Use of Antibiotics Best for COPD Flare-Ups 2Health News:Quick Use of Antibiotics Best for COPD Flare-Ups 3Health News:Indiana Home and Hospice Care Foundation Selects Pearson to Bolster Workforce Training Initiatives 2Health News:Indiana Home and Hospice Care Foundation Selects Pearson to Bolster Workforce Training Initiatives 3
... The FLU OIA test is a ... diagnosis of Influenza A and B with ... answer in just over 15 minutes. Assay ... specimen flexibility, and performance equivalent to 14-day ...
The CdTOX A OIA gets the results you need without specimen extraction or instrumentation. Results are available in minutes vs hours or days for EIA or other methods. The combination of performance, ...
... provides superior performance for the diagnosis ... that provides an answer in 6 ... will convince you of this tests ... deliver improved patient care with a ...
... for Botox therapy and nerve block ... injectable needle has a precisely machined ... with an attached 61-cm (24-in) lead ... insertion. Single patient use only. A ...
Medicine Products: